- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| ADVANZ PHARMA Aktie jetzt für 0€ handeln | |||||
| Mo | Alvotech announces European launch of first-in-market biosimilar to Simponi (golimumab) globally by partner Advanz Pharma | 239 | GlobeNewswire (Europe) | Introduction of AVT05 supported by NHS England tender award in the United Kingdom REYKJAVIK, ICELAND (December 22, 2025) - Alvotech (NASDAQ: ALVO), a global biotechnology company specializing in the... ► Artikel lesen | |
| 20.11. | Alvotech, Advanz Pharma secure European approval for Gobivaz, Simponi biosimilar | 3 | Seeking Alpha | ||
| 20.11. | Alvotech S.A.: Alvotech and Advanz Pharma Receive Marketing Approval Across the European Economic Area for Gobivaz, a First-in-Market Biosimilar to Simponi (golimumab) | 1.123 | GlobeNewswire (Europe) | Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide and Advanz Pharma Holdco Limited ("Advanz Pharma"), a... ► Artikel lesen | |
| 06.11. | Alvotech, Advanz Pharma Receive MHRA Marketing Authorizations for Gobivaz | 12 | Contract Pharma | ||
| 06.11. | Alvotech and Advanz Pharma Receive Marketing Authorisations for Gobivaz, a Biosimilar to Simponi (golimumab), from the MHRA | 353 | GlobeNewswire (Europe) | REYKJAVIK, ICELAND and LONDON, UK (November 06, 2025) - Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide... ► Artikel lesen | |
| 09.10. | EQS-News: Advanz Pharma treibt mit neuem Geschäftsführer für die DACH-Region, Dr. Piero Sciotto, Biosimilars-Strategie voran | 555 | EQS Group (DE) | EQS-News: Advanz Pharma Specialty Medicine Deutschland GmbH
/ Schlagwort(e): Personalie
Advanz Pharma treibt mit neuem Geschäftsführer für die DACH-Region... ► Artikel lesen | |
| 22.09. | European Medicines Agency Recommends Marketing Approval of Gobivaz, Alvotech's Proposed Biosimilar to Simponi (golimumab) with Advanz Pharma as Commercialization Partner | 399 | GlobeNewswire (Europe) | REYKJAVIK, ICELAND and LONDON, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients... ► Artikel lesen | |
| 21.08. | Alvotech, Advanz Pharma get EU nod for Eylea biosimilar | 9 | Seeking Alpha | ||
| 21.08. | Advanz Pharma & Alvotech Gain European Approval for Mynzepli | 5 | Contract Pharma | ||
| 21.08. | Advanz Pharma and Alvotech receive European approval for Mynzepli, Biosimilar to Eylea | 687 | GlobeNewswire (Europe) | Mynzepli® (aflibercept) is approved in all European Economic Area member countries for the treatment of various retinal diseases including neovascular (wet) age-related macular degeneration (AMD)Approval... ► Artikel lesen | |
| 06.07. | Alvotech (ALVO) Announces a Commercialization Agreement With Advanz Pharma | 5 | Insider Monkey | ||
| 01.07. | Alvotech and Advanz Pharma Enter into European Supply and Commercialization Agreement for Biosimilar Candidate to Cimzia (certolizumab pegol) | 664 | GlobeNewswire (Europe) | REYKJAVIK, Iceland and LONDON, July 01, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients... ► Artikel lesen | |
| 28.05. | Alvotech and Advanz Pharma Extend Strategic Partnership to Commercialize Three Additional Biosimilars in Europe | 613 | GlobeNewswire (Europe) | Advanz Pharma secures exclusive rights from Alvotech to commercialize three biosimilar candidates in Europe in addition to previously partnered programsThe agreement includes proposed biosimilars... ► Artikel lesen |
13 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| GILEAD SCIENCES | 106,00 | -0,17 % | ROUNDUP/Aktien New York Schluss: Erholung geht weiter | NEW YORK (dpa-AFX) - Die US-Börsen haben sich am Freitag weiter von ihrem jüngsten Rücksetzer erholt. Eine Jahresendrally sei nach wie vor möglich, sagte ein Investmentexperte. Es herrschte unvermindert... ► Artikel lesen | |
| BAUSCH HEALTH | 6,071 | -2,16 % | Bausch Health Companies Inc.: Bausch Health Announces Final Results and Expiration of Exchange Offers | LAVAL, QC / ACCESS Newswire / December 23, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) (the "Company") and its subsidiary 1261229 B.C. Ltd. (the "Issuer" and, together with the Company,... ► Artikel lesen | |
| IONIS PHARMACEUTICALS | 69,20 | +1,56 % | Cathie Woods ARK Invest setzt Verkäufe bei Ionis Pharma fort | ||
| WAVE LIFE SCIENCES | 14,900 | 0,00 % | Neuer Geheimtipp aus der Biotech-Szene - Wave Life Sciences hat sich zu Wochenbeginn mehr als verdoppelt! | Ist ein neuer Abnehm-Star geboren? Wave Life Sciences könnte mit einem bisher einzigartigen Wirkstoff den Adipositas-Markt aufmischen. Ein Ansatz, der Fett abbaut, Muskeln erhält und die Konkurrenz... ► Artikel lesen | |
| HARROW | 50,23 | +2,20 % | Harrow, Inc.: Harrow Health, Inc. Announces Closing of Acquisition of Melt Pharmaceuticals | NASHVILLE, Tenn., Nov. 18, 2025 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that it has completed the... ► Artikel lesen | |
| BRIGHT MINDS BIOSCIENCES | 84,66 | +0,46 % | Cantor Fitzgerald bestätigt "Overweight" für Bright Minds Biosciences und sieht Potenzial in Hauptwirkstoff BMB-101 | ||
| MILESTONE PHARMACEUTICALS | 2,075 | +6,41 % | Milestone Pharmaceuticals Inc.: Milestone Receives FDA Approval of CARDAMYST (etripamil) as First and Only Self-Administered Nasal Spray for Adults with Paroxysmal Supraventricular Tachycardia (PSVT) | First FDA approved treatment in 30+ years for more than 2 million Americans with PSVT Novel nasal spray designed to rapidly resolve episodes of PSVT and restore sinus rhythmFDA approval in PSVT enables... ► Artikel lesen | |
| LB PHARMACEUTICALS | 22,020 | -0,59 % | LB Pharmaceuticals Inc: LB Pharmaceuticals Appoints Kaya Pai Panandiker as Chief Commercial Officer | NEW YORK, Nov. 12, 2025 (GLOBE NEWSWIRE) -- LB Pharmaceuticals, Inc ("LB Pharmaceuticals" or the "Company") (Nasdaq: LBRX), a clinical-stage biopharmaceutical company developing novel therapies for... ► Artikel lesen | |
| AQUESTIVE THERAPEUTICS | 5,975 | +1,79 % | Aquestive Therapeutics, Inc.: Aquestive Therapeutics Broadens Patent Estate for Anaphylm | New patents extend protection for Anaphylm into 2037Anaphylm (dibutepinephrine) Sublingual Film, if approved by the FDA, will be the first and only oral medication for the rescue treatment of severe... ► Artikel lesen | |
| CITIUS PHARMACEUTICALS | 0,803 | -22,82 % | Citius Pharmaceuticals, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update |
Subsidiary, Citius Oncology, launches cancer immunotherapy, LYMPHIR, in the U.S. in December 2025
CRANFORD, N.J., Dec. 23, 2025 /PRNewswire/ -- Citius Pharmaceuticals... ► Artikel lesen | |
| KAZIA THERAPEUTICS | 8,000 | -6,76 % | Kazia Therapeutics Limited: Kazia Therapeutics Regains Full Nasdaq Listing Compliance | Restoration of Nasdaq compliance follows $50 million institutional financing and reinforces balance-sheet strength
SYDNEY, Dec. 22, 2025 /PRNewswire/ -- Kazia Therapeutics... ► Artikel lesen | |
| ETON PHARMACEUTICALS | 17,010 | +2,78 % | Eton Pharmaceuticals Announces FDA Acceptance of New Drug Application for ET-600 (Desmopressin Oral Solution) | - NDA assigned a Target Action Date of February 25, 2026 -- Product has patent protection through 2044 - DEER PARK, Ill., July 08, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc ("Eton" or the... ► Artikel lesen | |
| REVIVA PHARMACEUTICALS | 0,278 | -13,48 % | Reviva Pharmaceuticals: Reviva Announces Regulatory Update Regarding the Development of Brilaroxazine for the Treatment of Schizophrenia | Written feedback from FDA pre-NDA meeting includes a recommendation to conduct a second Phase 3 trial to generate additional efficacy and safety data prior to NDA submission of brilaroxazine for the... ► Artikel lesen | |
| NOVABAY PHARMACEUTICALS | 4,690 | +1,63 % | NovaBay Pharmaceuticals, Inc. Regains Compliance with NYSE American Continued Listing Standards | EMERYVILLE, Calif., Oct. 20, 2025 (GLOBE NEWSWIRE) -- NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) ("NovaBay" or the "Company") announces that it has regained compliance with the NYSE American's... ► Artikel lesen | |
| OMNIAB | 1,960 | +1,03 % | OmniAb outlines $18M-$22M 2025 revenue guidance while launching OmniUltra and expanding xPloration platform |
ADVANZ PHARMA CORP LIMITED gehört der Branche Pharma an.
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ADVANZ PHARMA CORP LIMITED finden Sie auf Wallstreet Online.